Post

New research · Rheumatology
Cell proliferation · 2d
Cohort studyCell proliferation · 2026

Immune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.

Lipeng Tang, Maojie Wang, Yuhong Yan … Chuanjian Lu
Read paper
RheumatologyCohort study

A three-gene model accurately identifies Dampness ZHENG in autoimmune diseases.

Immune Repertoire Profiling Reveals Distinct Adaptive Immune Signatures of Dampness ZHENG Across Psoriasis, Rheumatoid Arthritis and Ulcerative Colitis.

Lipeng Tang et al. · Cell proliferation · 2026
Background

Autoimmune diseases, including psoriasis (Ps), rheumatoid arthritis (RA) and ulcerative colitis (UC), pose significant health burdens worldwide.

Methods

In this study, we performed comprehensive T cell receptor (TCR) and B cell receptor (BCR) repertoire sequencing in 59 participants, including patients with Ps, RA, UC and healthy controls.

n = 59 participants
AUC of 0.804
Results
how well the three-gene model identifies Dampness ZHENG
n = 59 participants
More results

A more refined classification of these diseases is essential for enabling targeted therapeutic strategies.

Compared with healthy controls, Ps, RA and UC patients exhibited reduced clonotype richness and diminished TCR/BCR diversity, indicating adaptive immune contraction.

More results

Stratification by Dampness ZHENG revealed distinct immune repertoire architectures characterized by increased D50 index, reduced proportions of large clones and preferential V gene usage, including TRAV20, TRAV38-2DV8 and TRAV8-3.

“
Conclusion

Our findings suggest that TCM-based phenotyping may offer a meaningful approach for subgrouping autoimmune diseases, thereby providing a foundation for more syndrome differentiation-based treatment strategies.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Review
34.6%
Complete renal remission was achieved in 34.6% of patients receiving high-dose glucocorticoids.
Cohort Study
HR 3.3
any ultrasound finding at baseline means a 3-fold higher chance of developing arthritis
Cohort Study
OR = 0.220
belimumab was linked to a lower chance of lupus kidney disease symptoms returning